Value sets for scoring the EQ-5D
EQ-5D value sets (or tariffs) are comprehensive, country-specific lists of numerical values (utilities/scores) assigned to every possible EQ-5D health state profile, anchoring full health at 1 and dead at 0. Value sets are typically derived from studies involving samples of people from the general population and reflect societal preferences. Value sets are specific to countries or regions because preferences for health states vary globally. EQ-5D values may be used to calculate Quality-Adjusted Life-Years (QALYs) for health technology assessment.
Below, you will find tools which will help you calculate EQ-5D values for our two adult instruments (EQ-5D-3L and EQ-5D-5L) and for our original youth instrument (EQ-5D-Y-3L) according to the country or region you are interested in. Select the instrument and country/region using the drop-down menus to show a list of currently available tools (e.g. STATA, SAS, SPSS, R, excel).
For our newer youth instrument, the EQ-5D-Y-5L, EuroQol is developing a protocol for the valuation of EQ-5D-Y-5L health states – once finalized, value sets will be developed. It is anticipated that a limited number of value sets will become available in 2027. In addition, EuroQol is developing a crosswalk function which will allow users to link individual responses on the EQ-5D-Y-5L descriptive system with existing EQ-5D-Y-3L value sets.
An introduction to EQ-5D value sets
* Disclaimer: Whilst the EQ Foundation and EQ Office make its outmost effort in presenting accurate and up-to-date tools, the EQ Foundation and EQ Office make no representation or warranty on the correctness, adequacy, accuracy and completeness of the tools presented here, nor do warrant that the tools shall be complete in every respect. The EQ Foundation and EQ Office shall have no responsibility nor liability resulting from the use of these tools, nor for the absence of information on the site, which results in misuse thereof.
(Use the filter buttons below to quickly find the version(s) you need.)
| Country / Region | Instrument | Publication | Protocol | Value Set STATA | Value Set SAS | Value Set SPSS |
|---|---|---|---|---|---|---|
| Argentina | EQ-5D-3L | Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, Craig BM. Argentine valuation of the EQ-5D health states. Value Health. 2009;12(4):587-96. | pre-EQ-VT TTO | Argentina 3L (Augustovski TTO 2009) | Argentina 3L (Augustovski TTO 2009) | Argentina 3L (Augustovski TTO 2009) |
| Argentina | EQ-5D-3L | Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, Craig BM. Argentine valuation of the EQ-5D health states. Value Health. 2009;12(4):587-96. | pre-EQ-VT VAS | Argentina 3L (Augustovski VAS 2009).txt | Argentina 3L (Augustovski VAS 2009) | Argentina 3L (Augustovski VAS 2009) |
| Australia | EQ-5D-3L | Viney R, Norman R, King MT, Cronin P, Street DJ, Knox S, Ratcliffe J. Time trade-off derived EQ-5D weights for Australia. Value Health. 2011;14(6):928-36. | pre-EQ-VT TTO | Australia 3L (Viney TTO 2011).txt | Australia 3L (Viney TTO 2011) | Australia 3L (Viney TTO 2011) |
| Australia | EQ-5D-5L | Norman R, Mulhern B, Lancsar E, Lorgelly P, Ratcliffe J, Street D, Viney R. The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. Pharmacoeconomics. 2023 Apr;41(4):427-438. | Other | Australia 5L (Norman DCE 2023).txt | Australia 5L (Norman DCE 2023) | Australia 5L (Norman DCE 2023) |
| Australia | EQ-5D-Y-3L | Pan T, Roudijk B, Devlin N, Mulhern B, Norman R. An Australian Value Set for the EQ-5D-Y-3L. Health Qual Life Outcomes. 2025 Jul 15;23(1):72. | Ramos-Goni et al (2020) | Australia Y-3L (Pan DCE TTO 2025) | Australia Y-3L (Pan DCE TTO 2025) | Australia Y-3L (Pan DCE TTO 2025) |
| Belgium | EQ-5D-3L | Cleemput I. A social preference valuations set for EQ-5D health states in Flanders, Belgium. Eur J Health Econ. 2010;11(2):205-13. | pre-EQ-VT VAS | Belgium 3L (Cleemput VAS 2010).txt | Belgium 3L (Cleemput VAS 2010) | Belgium 3L (Cleemput VAS 2010) |
| Belgium | EQ-5D-5L | Bouckaert N, Cleemput I, Devriese S, Gerkens S. An EQ-5D-5L Value Set for Belgium. Pharmacoecon Open. 2022 Nov;6(6):823-836. | EQ-VT v2.1 | Belgium 5L (Bouckaert Hybrid 2022).txt | Belgium 5L (Bouckaert Hybrid 2022) | Belgium 5L (Bouckaert Hybrid 2022) |
| Belgium | EQ-5D-Y-3L | Dewilde S, Roudijk B, Tollenaar NH, Ramos-Goñi JM. An EQ-5D-Y-3L Value Set for Belgium. Pharmacoeconomics. 2022;40(Suppl 2):169-180. | Ramos-Goni et al (2020) | Belgium Y-3L (Dewilde DCE TTO 2022).txt | Belgium Y-3L (Dewilde DCE TTO 2022) | Belgium Y-3L (Dewilde DCE TTO 2022) |
| Bermuda | EQ-5D-3L | Bailey H, Roudijk B, Brathwaite R. The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol. Eur J Health Econ. 2025;26(2):275-297. | EQ-VT v2.1 | Bermuda 3L (Bailey EQ-VT 2025).txt | Bermuda 3L (Bailey EQ-VT 2025) | Bermuda 3L (Bailey EQ-VT 2025) |
| Brazil | EQ-5D-3L | Viegas Andrade M, Noronha K, Kind P, Maia AC, de Menezes RM, de Barros Reis C, Nepomuceno Souza M, Martins D, Gomes L, Nichele D, Calazans J, Mascarenhas T, Carvalho L, Lins C. Societal Preferences for EQ-5D Health States from a Brazilian Population Survey. Value in Health Regional Issues 2013;2(3):405Ð412. | pre-EQ-VT TTO | Brazil 3L (Andrade TTO 2013).txt | Brazil 3L (Andrade TTO 2013) | Brazil 3L (Andrade TTO 2013) |
| Brazil | EQ-5D-3L | Santos M, Cintra MA, Monteiro AL, Santos B, Gusmão-Filho F, Andrade MV, Noronha K, Cruz LN, Camey S, Tura B, Kind P Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study. Med Decis Making. 2016 Feb;36(2):253-63 | pre-EQ-VT TTO | Brazil 3L (Santos TTO 2016).txt | Brazil 3L (Santos TTO 2016) | Brazil 3L (Santos TTO 2016) |
| Brazil | EQ-5D-Y-3L | Espirito Santo CM, Miyamoto GC, Santos VS, Ben ÂJ, Finch AP, Roudijk B, de Jesus-Moraleida FR, Stein AT, Santos M, Yamato TP. Estimating an EQ-5D-Y-3L Value Set for Brazil. Pharmacoeconomics. 2024;42(9):1047-1063. | Ramos-Goni et al (2020) | Brazil Y-3L (Santo DCE TTO 2024).txt | Brazil Y-3L (Santo DCE TTO 2024) | Brazil Y-3L (Santo DCE TTO 2024) |
| Canada | EQ-5D-3L | Bansback, N., Tsuchiya A, Brazier J, et al. Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies. PLoS ONE. 2012; 7(2), e31115. | pre-EQ-VT TTO | Canada 3L (Bansback TTO 2012).txt | Canada 3L (Bansback TTO 2012) | Canada 3L (Bansback TTO 2012) |
| Canada | EQ-5D-5L | Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA; Canadian EQ-5D-5L Valuation Study Group. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care. 2016 Jan;54(1):98-105. | EQ-VT v1.0 | Canada 5L (Xie TTO 2016).txt | Canada 5L (Xie TTO 2016) | Canada 5L (Xie TTO 2016) |
| Chile | EQ-5D-3L | Zarate V, Kind P, Valenzuela P, et al. Social valuation of EQ-5D health states: the Chilean case. Value Health, 14 (2011), pp. 1135-1141. | pre-EQ-VT TTO | Chile 3L (Zarate TTO 2011).txt | Chile 3L (Zarate TTO 2011) | Chile 3L (Zarate TTO 2011) |
| China | EQ-5D-3L | Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597-604. | pre-EQ-VT TTO | China 3L (Liu TTO 2014).txt | China 3L (Liu TTO 2014) | China 3L (Liu TTO 2014) |
| China | EQ-5D-3L | Zhuo L, Xu L, Ye J, et al. Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey. Value in Health May 2018. | pre-EQ-VT TTO | China 3L (Zhuo TTO 2018).txt | China 3L (Zhuo TTO 2018) | China 3L (Zhuo TTO 2018) |
| China | EQ-5D-5L | Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L Value Set for China. Value Health. 2017 Apr;20(4):662-669. | EQ-VT v1.0 | China 5L (Luo TTO 2017).txt | China 5L (Luo TTO 2017) | China 5L (Luo TTO 2017) |
| China | EQ-5D-Y-3L | Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, Feng D, Xi X, Li S, Jing M, Zheng B, Huang W, Luo N. Estimating an EQ-5D-Y-3L Value Set for China. Pharmacoeconomics. 2022;40(Suppl 2):147-155. | Ramos-Goni et al (2020) | China Y-3L (Yang DCE TTO 2022).txt | China Y-3L (Yang DCE TTO 2022) | China Y-3L (Yang DCE TTO 2022) |
| Denmark | EQ-5D-3L | Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health. 2009;37(5):459-66. | pre-EQ-VT TTO | Denmark 3L (Wittrup-Jensen TTO 2009).txt | Denmark 3L (Wittrup-Jensen TTO 2009) | Denmark 3L (Wittrup-Jensen TTO 2009) |
| Denmark | EQ-5D-3L | Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health. 2009;37(5):459-66. | pre-EQ-VT VAS | Denmark 3L (Wittrup-Jensen VAS 2009).txt | Denmark 3L (Wittrup-Jensen VAS 2009) | Denmark 3L (Wittrup-Jensen VAS 2009) |
| Denmark | EQ-5D-5L | Jensen CE, Sørensen SS, Gudex C, Jensen MB, Pedersen KM, Ehlers LH. The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data. Appl Health Econ Health Policy. 2021 Jul;19(4):579-591. | EQ-VT v2.1 | Denmark 5L (Jensen Hybrid 2021).txt | Denmark 5L (Jensen Hybrid 2021) | Denmark 5L (Jensen Hybrid 2021) |
| Egypt | EQ-5D-5L | Al Shabasy S, Abbassi M, Finch A, Roudijk B, Baines D, Farid S. The EQ-5D-5L Valuation Study in Egypt. Pharmacoeconomics. 2022 Apr;40(4):433-447. | EQ-VT v2.1 | Egypt 5L (Al Shabasy TTO 2022).txt | Egypt 5L (Al Shabasy TTO 2022) | Egypt 5L (Al Shabasy TTO 2022) |
| Ethiopia | EQ-5D-5L | Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. Value Health Reg Issues. 2020 Sep;22:7-14. | EQ-PVT | Ethiopia 5L (Welie Hybrid 2020).txt | Ethiopia 5L (Welie Hybrid 2020) | Ethiopia 5L (Welie Hybrid 2020) |
| Europe | EQ-5D-3L | Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Eur J Health Econ 2003; 4(3):222-231. | pre-EQ-VT VAS | Europe from six countries 3L (Greiner VAS 2003).txt | Europe from six countries 3L (Greiner VAS 2003) | Europe from six countries 3L (Greiner VAS 2003) |
| Finland | EQ-5D-3L | Ohinmaa A, Sintonen H. Inconsistencies and modelling of the Finnish EuroQol (EQ-5D) preference values. In: Greiner W, J-M. Graf v.d. Schulenburg, Piercy J, editors. EuroQol Plenary Meeting, 1-2 October 1998. Discussion papers. Centre for Health Economics and Health Systems Research, University of Hannover, Germany. Uni-Verlag Witte, 1999; 57-74. | pre-EQ-VT VAS | Finland 3L (Ohinmaa VAS 1998).txt | Finland 3L (Ohinmaa VAS 1998) | Finland 3L (Ohinmaa VAS 1998) |
| France | EQ-5D-3L | Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57-66. | pre-EQ-VT TTO | France 3L (Chevalier TTO 2013).txt | France 3L (Chevalier TTO 2013) | France 3L (Chevalier TTO 2013) |
| France | EQ-5D-5L | Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French Value Set for the EQ-5D-5L. Pharmacoeconomics. 2020 Apr;38(4):413-425. | EQ-VT v2.0 | France 5L (Andrade Hybrid 2020).txt | France 5L (Andrade Hybrid 2020) | France 5L (Andrade Hybrid 2020) |
| Germany | EQ-5D-3L | Greiner W, Claes C, Buschbach JJV, Graf von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005;6(2):124-130. | pre-EQ-VT TTO | Germany 3L (Greiner TTO 2005).txt | Germany 3L (Greiner TTO 2005) | Germany 3L (Greiner TTO 2005) |
| Germany | EQ-5D-5L | Ludwig K, Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018 Jun;36(6):663-674. | EQ-VT v2.0 | Germany 5L (Ludwig Hybrid 2018).txt | Germany 5L (Ludwig Hybrid 2018) | Germany 5L (Ludwig Hybrid 2018) |
| Germany | EQ-5D-Y-3L | Kreimeier S, Mott D, Ludwig K, Greiner W; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Germany. Pharmacoeconomics. 2022;40(Suppl 2):217-229. | Ramos-Goni et al (2020) | Germany Y-3L (Kreimeier DCE TTO 2022).txt | Germany Y-3L (Kreimeier DCE TTO 2022) | Germany Y-3L (Kreimeier DCE TTO 2022) |
| Ghana | EQ-5D-5L | Addo R, Mulhern B, Norman R, Owusu R, Viney R, Nonvignon J. An EQ-5D-5L Value Set for Ghana Using an Adapted EuroQol Valuation Technology Protocol. Value Health Reg Issues. 2025 Jan;45:101045. | EQ-VT v2.1 | Ghana 5L (Addo Hybrid 2025).txt | Ghana 5L (Addo Hybrid 2025) | Ghana 5L (Addo Hybrid 2025) |
| Hong Kong | EQ-5D-5L | Wong ELY, Ramos-Goñi JM, Cheung AWL, Wong AYK, Rivero-Arias O. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. Patient. 2018 Apr;11(2):235-247. | EQ-VT v1.1 | Hong Kong 5L (Wong Hybrid 2018).txt | Hong Kong 5L (Wong Hybrid 2018) | Hong Kong 5L (Wong Hybrid 2018) |
| Hungary | EQ-5D-3L | Rencz F, Brodszky V, Gulacsi L, Golicki D, Ruzsa G, Pickard S, Law E, Pentek M. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value in Health. 2020; 23(9):1235–1245 | EQ-VT v2.1 | Hungary 3L (Rencz TTO 2020).txt | Hungary 3L (Rencz TTO 2020) | Hungary 3L (Rencz TTO 2020) |
| Hungary | EQ-5D-5L | Rencz F, Brodszky V, Gulacsi L, Golicki D, Ruzsa G, Pickard S, Law E, Pentek M. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value in Health. 2020; 23(9):1235–1245 | EQ-VT v2.1 | Hungary 5L (Rencz TTO 2020).txt | Hungary 5L (Rencz TTO 2020) | Hungary 5L (Rencz TTO 2020) |
| Hungary | EQ-5D-Y-3L | Rencz F, Ruzsa G, Bató A, Yang Z, Finch AP, Brodszky V. Value Set for the EQ-5D-Y-3L in Hungary. Pharmacoeconomics. 2022;40(Suppl 2):205-215. | Ramos-Goni et al (2020) | Hungary Y-3L (Rencz DCE TTO 2022).txt | Hungary Y-3L (Rencz DCE TTO 2022) | Hungary Y-3L (Rencz DCE TTO 2022) |
| India | EQ-5D-5L | Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, Goyal A, Purba FD, Finch AP, Rajsekar K, Raman S, Stolk E, Kaur M. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set. Value Health. 2022 Jul;25(7):1218-1226. | EQ-VT v2.1 | India 5L (Jyani Hybrid 2022).txt | India 5L (Jyani Hybrid 2022) | India 5L (Jyani Hybrid 2022) |
| Indonesia | EQ-5D-5L | Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Ramos-Goñi JM, Passchier J, Busschbach JJV. The Indonesian EQ-5D-5L Value Set. Pharmacoeconomics. 2017 Nov;35(11):1153-1165. | EQ-VT v2.0 | Indonesia 5L (Purba Hybrid 2017).txt | Indonesia 5L (Purba Hybrid 2017) | Indonesia 5L (Purba Hybrid 2017) |
| Indonesia | EQ-5D-Y-3L | Fitriana TS, Roudijk B, Purba FD, Busschbach JJV, Stolk E. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values. Pharmacoeconomics. 2022;40(Suppl 2):157-167. | Ramos-Goni et al (2020) | Indonesia Y-3L (Fitiriana DCE TTO 2022).txt | Indonesia Y-3L (Fitiriana DCE TTO 2022) | Indonesia Y-3L (Fitiriana DCE TTO 2022) |
| Iran | EQ-5D-3L | Goudarzi R, Sari AA, Zeraati H, Rashidian A, Mohammad K, Amini S. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran. Value Health Reg Issues. 2019 May 13;18:170-175 | pre-EQ-VT TTO | Iran 3L (Goudarzi TTO 2019).txt | Iran 3L (Goudarzi TTO 2019) | Iran 3L (Goudarzi TTO 2019) |
| Iran | EQ-5D-5L | Afshari S, Daroudi R, Goudarzi R, Mahboub-Ahari A, Yaseri M, Sari AA, Ameri H, Bahariniya S, Oliaei-Manesh A, Kalavani K, Zare Z, Hasannezhad E, Mirzaei M, Amiri Z. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L. Qual Life Res. 2023 Jul;32(7):2079-2087. | EQ-PVT | Iran 5L (Afshari Hybrid 2023).txt | Iran 5L (Afshari Hybrid 2023) | Iran 5L (Afshari Hybrid 2023) |
| Ireland | EQ-5D-5L | Hobbins A, Barry L, Kelleher D, Shah K, Devlin N, Goni JMR, O'Neill C. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018 Nov;36(11):1345-1353. | EQ-VT v2.0 | Ireland 5L (Hobbins Hybrid 2018).txt | Ireland 5L (Hobbins Hybrid 2018) | Ireland 5L (Hobbins Hybrid 2018) |
| Italy | EQ-5D-3L | Scalone L, Cortesi PA, Ciampichini R, Belisari A, D'Angiolella LS, Cesana G, Mantovani LG.Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814-22. | pre-EQ-VT TTO | Italy 3L (Scalone TTO 2013).txt | Italy 3L (Scalone TTO 2013) | Italy 3L (Scalone TTO 2013) |
| Italy | EQ-5D-5L | Finch AP, Meregaglia M, Ciani O, Roudijk B, Jommi C. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med. 2022 Jan;292:114519. | EQ-VT v2.1 | Italy 5L (Finch Hybrid 2022).txt | Italy 5L (Finch Hybrid 2022) | Italy 5L (Finch Hybrid 2022) |
| Japan | EQ-5D-3L | Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: The case of Japan. Health Economics 2002; 11(4):341-353. | pre-EQ-VT TTO | Japan 3L (Tsuchiya TTO 2002).txt | Japan 3L (Tsuchiya TTO 2002) | Japan 3L (Tsuchiya TTO 2002) |
| Japan | EQ-5D-5L | Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value Health. 2016 Jul-Aug;19(5):648-54. | EQ-VT v1.1 | Japan 5L (Shiroiwa TTO 2016).txt | Japan 5L (Shiroiwa TTO 2016) | Japan 5L (Shiroiwa TTO 2016) |
| Japan | EQ-5D-Y-3L | Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021;41(5):597-606. | Ramos-Goni et al (2020) | Japan Y-3L (Shiroiwa DCE TTO 2021).txt | Japan Y-3L (Shiroiwa DCE TTO 2021) | Japan Y-3L (Shiroiwa DCE TTO 2021) |
| Jordan | EQ-5D-3L | Rabayah A, Roudijk B, Purba FD, Rencz F, Saad Jaddoua S, Siebert U. Valuation of the EQ-5D-3L in Jordan. Eur J Health Econ. 2025;26(3):487-501. | EQ-VT v2.1 | Jordan 3L (Al Rabayah Hybrid 2025).txt | Jordan 3L (Al Rabayah Hybrid 2025) | Jordan 3L (Al Rabayah Hybrid 2025) |
| Kingdom of Saudi Arabia | EQ-5D-5L | Al-Jedai A, Almudaiheem H, Al-Salamah T, Aldosari M, Almutairi AR, Almogbel Y, AlRuthia Y, Althemery AU, Alluhidan M, Roudijk B, Purba FD, Awad N, O'jeil R. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study. Value Health, 2024 May;27(5):552-561 | EQ-VT v2.1 | Kingdom of Saudi Arabia 5L (Al-Jedai Hybrid 2024).txt | Kingdom of Saudi Arabia 5L (Al-Jedai Hybrid 2024) | Kingdom of Saudi Arabia 5L (Al-Jedai Hybrid 2024) |
| Malaysia | EQ-5D-3L | Yusof FA, Goh A, Azmi S. Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods. Value Health. 2012;15(1 Suppl):S85-90. | pre-EQ-VT VAS | Malaysia 3L (Yusof VAS 2012).txt | Malaysia 3L (Yusof VAS 2012) | Malaysia 3L (Yusof VAS 2012) |
| Malaysia | EQ-5D-5L | Shafie AA, Vasan Thakumar A, Lim CJ, Luo N, Rand-Hendriksen K, Md Yusof FA. EQ-5D-5L Valuation for the Malaysian Population. Pharmacoeconomics. 2019 May;37(5):715-725. | EQ-VT v2.0 | Malaysia 5L (Shafie Hybrid 2019).txt | Malaysia 5L (Shafie Hybrid 2019) | Malaysia 5L (Shafie Hybrid 2019) |
| Mexico | EQ-5D-5L | Gutierrez-Delgado C, Galindo-Suárez RM, Cruz-Santiago C, Shah K, Papadimitropoulos M, Feng Y, Zamora B, Devlin N. EQ-5D-5L Health-State Values for the Mexican Population. Appl Health Econ Health Policy. 2021 Nov;19(6):905-914. | EQ-VT v2.1 | Mexico 5L (Gutierrez-Delgado TTO 2021).txt | Mexico 5L (Gutierrez-Delgado TTO 2021) | Mexico 5L (Gutierrez-Delgado TTO 2021) |
| Morocco | EQ-5D-5L | Azizi A, Boutib A, Achak D, Purba FD, Rencz F, Saad E, Hilali A, Ahid S, Nejjari C, Stolk EA, Roudijk B, Youlyouz-Marfak I, Marfak A. Valuing health-related quality of life: an EQ-5D-5L value set for Morocco. Qual Life Res. 2025 Jun;34(6):1783-1796. | EQ-VT v2.1 | Morocco 5L (Azizi Hybrid 2025).txt | Morocco 5L (Azizi Hybrid 2025) | Morocco 5L (Azizi Hybrid 2025) |
| Netherlands | EQ-5D-3L | Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006;15(10):1121-32. | pre-EQ-VT TTO | Netherlands 3L (Lamers TTO 2006).txt | Netherlands 3L (Lamers TTO 2006) | Netherlands 3L (Lamers TTO 2006) |
| Netherlands | EQ-5D-5L | Versteegh MM, Vermeulen KM, Evers SM, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016;19(4):343-52. | EQ-VT v1.0 | Netherlands 5L (Versteegh TTO 2016).txt | Netherlands 5L (Versteegh TTO 2016) | Netherlands 5L (Versteegh TTO 2016) |
| Netherlands | EQ-5D-Y-3L | Roudijk B, Sajjad A, Essers B, Lipman S, Stalmeier P, Finch AP. A Value Set for the EQ-5D-Y-3L in the Netherlands. Pharmacoeconomics. 2022;40(Suppl 2):193-203. | Ramos-Goni et al (2020) | Netherlands Y-3L (Roudijk DCE TTO 2022).txt | Netherlands Y-3L (Roudijk DCE TTO 2022) | Netherlands Y-3L (Roudijk DCE TTO 2022) |
| New Zealand | EQ-5D-3L | Devlin NJ, Hansen P, Kind P, Williams, A.Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Econ 2003; 12(7):529-544. | pre-EQ-VT VAS | New Zealand 3L (Devlin VAS 2003).txt | New Zealand 3L (Devlin VAS 2003) | New Zealand 3L (Devlin VAS 2003) |
| New Zealand | EQ-5D-5L | Sullivan T, Hansen P, Ombler F, Derrett S, Devlin N. A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead'. Soc Sci Med. 2020 Feb;246:112707. | Other | New Zealand 5L (Sullivan DCE 2020).txt | New Zealand 5L (Sullivan DCE 2020) | New Zealand 5L (Sullivan DCE 2020) |
| Norway | EQ-5D-5L | Garratt AM, Stavem K, Shaw JW, Rand K. EQ-5D-5L value set for Norway: a hybrid model using cTTO and DCE data. Qual Life Res. 2025 Feb;34(2):417-427. | EQ-VT v2.1 | Norway 5L (Garratt Hybrid 2025).txt | Norway 5L (Garratt Hybrid 2025) | Norway 5L (Garratt Hybrid 2025) |
| Pakistan | EQ-5D-3L | Malik M, Gu NY, Hussain A, Roudijk B, Purba FD. The EQ-5D-3L Valuation Study in Pakistan. Pharmacoecon Open. 2023 Nov;7(6):963-974. | EQ-PVT | Pakistan 3L (Malik Hybrid 2023).txt | Pakistan 3L (Malik Hybrid 2023) | Pakistan 3L (Malik Hybrid 2023) |
| Peru | EQ-5D-5L | Augustovski F, Belizán M, Gibbons L, Reyes N, Stolk E, Craig B, Tejada R. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments. Value Health. 2020 Jul;23(7):880-888. | EQ-VT Lite | Peru 5L (Augustovski TTO 2020).txt | Peru 5L (Augustovski TTO 2020) | Peru 5L (Augustovski TTO 2020) |
| Philippines | EQ-5D-5L | Miguel RTD, Rivera AS, Cheng KJG, Rand K, Purba FD, Luo N, Zarsuelo MA, Genuino-Marfori AJ, Florentino-Fariñas I, Guerrero AM, Lam HY. Estimating the EQ-5D-5L value set for the Philippines. Qual Life Res. 2022 Sep;31(9):2763-2774. | EQ-VT v2.0 | Philippines 5L (Miguel TTO 2022).txt | Philippines 5L (Miguel TTO 2022) | Philippines 5L (Miguel TTO 2022) |
| Poland | EQ-5D-3L | Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach JJ.Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health. 2010;13(2):289-97. | pre-EQ-VT TTO | Poland 3L (Golicki TTO 2010).txt | Poland 3L (Golicki TTO 2010) | Poland 3L (Golicki TTO 2010) |
| Poland | EQ-5D-5L | Golicki D, Jakubczyk M, Graczyk K, Niewada M. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe. Pharmacoeconomics. 2019 Sep;37(9):1165-1176. | EQ-VT v2.0 | Poland 5L (Golicki Hybrid 2019).txt | Poland 5L (Golicki Hybrid 2019) | Poland 5L (Golicki Hybrid 2019) |
| Portugal | EQ-5D-3L | Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014;23(2):413-23 | pre-EQ-VT TTO | Portugal 3L (Ferreira TTO 2014).txt | Portugal 3L (Ferreira TTO 2014) | Portugal 3L (Ferreira TTO 2014) |
| Portugal | EQ-5D-5L | Ferreira PL, Antunes P, Ferreira LN, Pereira LN, Ramos-Goñi JM. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Qual Life Res. 2019 Dec;28(12):3163-3175. | EQ-VT v2.0 | Portugal 5L (Ferreira Hybrid 2019).txt | Portugal 5L (Ferreira Hybrid 2019) | Portugal 5L (Ferreira Hybrid 2019) |
| Romania | EQ-5D-3L | Paveliu M, Olariu E, Caplescu R, Oluboyede Y, Niculescu-Aron I, Ernu S, Vale L; Estimating an EQ-5D-3L value set for Romania using time trade-off. Environmental Research and Public Health, 18(14), 7415. | EQ-VT v2.1 | Romania 3L (Paveliu TTO 2021).txt | Romania 3L (Paveliu TTO 2021) | Romania 3L (Paveliu TTO 2021) |
| Romania | EQ-5D-5L | Olariu E, Mohammed W, Oluboyede Y, Caplescu R, Niculescu-Aron IG, Paveliu MS, Vale L. EQ-5D-5L: a value set for Romania. Eur J Health Econ. 2023 Apr;24(3):399-412. | EQ-VT v2.1 | Romania 5L (Olariu Hybrid 2023).txt | Romania 5L (Olariu Hybrid 2023) | Romania 5L (Olariu Hybrid 2023) |
| Russia | EQ-5D-3L | Omelyanovskiy V, Musina N, Ratushnyak S, Bezdenezhnykh T, Fediaeva V, Roudijk B, Purba FD. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. | EQ-VT v2.1 | Russia 3L (Omelyanovskiy Hybrid 2021).txt | Russia 3L (Omelyanovskiy Hybrid 2021) | Russia 3L (Omelyanovskiy Hybrid 2021) |
| Singapore | EQ-5D-3L | Luo N, Wang P, Thumboo J, Lim YW, Vrijhoef HJ. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics. 2014;32(5):495-507 | pre-EQ-VT TTO | Singapore 3L (Luo TTO 2014).txt | Singapore 3L (Luo TTO 2014) | Singapore 3L (Luo TTO 2014) |
| Slovenia | EQ-5D-3L | Prevolnik Rupel V, Srakar A, Rand K. Valuation of EQ-5D-3l Health States in Slovenia: VAS Based and TTO Based Value Sets. Zdr Varst. 2019 Dec 13;59(1):8-17 | pre-EQ-VT TTO | Slovenia 3L (Rupel TTO 2019).txt | Slovenia 3L (Rupel TTO 2019) | Slovenia 3L (Rupel TTO 2019) |
| Slovenia | EQ-5D-3L | Prevolnik Rupel V, Srakar A, Rand K. Valuation of EQ-5D-3l Health States in Slovenia: VAS Based and TTO Based Value Sets. Zdr Varst. 2019 Dec 13;59(1):8-17 | pre-EQ-VT VAS | Slovenia 3L (Rupel VAS 2019).txt | Slovenia 3L (Rupel VAS 2019) | Slovenia 3L (Rupel VAS 2019) |
| Slovenia | EQ-5D-5L | Prevolnik Rupel V, Ogorevc M. EQ-5D-5L Value Set for Slovenia. Pharmacoeconomics. 2023 Nov;41(11):1515-1524. | EQ-VT v2.1 | Slovenia 5L (Rupel TTO 2023) | Slovenia 5L (Rupel TTO 2023) | Slovenia 5L (Rupel TTO 2023) |
| Slovenia | EQ-5D-Y-3L | Prevolnik Rupel V, Ogorevc M; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Slovenia. Pharmacoeconomics. 2021;39(4):463-471. | Ramos-Goni et al (2020) | Slovenia Y-3L (Rupel DCE TTO 2021).txt | Slovenia Y-3L (Rupel DCE TTO 2021) | Slovenia Y-3L (Rupel DCE TTO 2021) |
| South Korea | EQ-5D-3L | Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, Kind P, Kweon SS, Kim YT.South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health. 2009;12(8):1187-93. | pre-EQ-VT TTO | South Korea 3L (Lee TTO 2009).txt | South Korea 3L (Lee TTO 2009) | South Korea 3L (Lee TTO 2009) |
| South Korea | EQ-5D-5L | Kim SH, Ahn J, Ock M, Shin S, Park J, Luo N, Jo MW. The EQ-5D-5L valuation study in Korea. Qual Life Res. 2016 Jul;25(7):1845-52. | EQ-VT v1.1 | South Korea 5L (Kim TTO 2016).txt | South Korea 5L (Kim TTO 2016) | South Korea 5L (Kim TTO 2016) |
| Spain | EQ-5D-3L | Badia X, Roset R, Herdman, M, Kind P.A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001; 21(1): 7-16. | pre-EQ-VT TTO | Spain 3L (Badia TTO 2001).txt | Spain 3L (Badia TTO 2001) | Spain 3L (Badia TTO 2001) |
| Spain | EQ-5D-5L | Ramos-Goñi JM, Craig BM, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, Rivero-Arias O. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Value Health. 2018 May;21(5):596-604. | EQ-VT v1.0 | Spain 5L (Ramos-Goñi Hybrid 2018).txt | Spain 5L (Ramos-Goñi Hybrid 2018) | Spain 5L (Ramos-Goñi Hybrid 2018) |
| Spain | EQ-5D-Y-3L | Ramos-Goñi JM, Oppe M, Estévez-Carrillo A, Rivero-Arias O; IMPACT HTA HRQoL Group. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data. Value Health. 2022;25(5):835-843. | Ramos-Goni et al (2020) | Spain Y-3L (Ramos-Goñi DCE TTO 2022).txt | Spain Y-3L (Ramos-Goñi DCE TTO 2022) | Spain Y-3L (Ramos-Goñi DCE TTO 2022) |
| Sri Lanka | EQ-5D-3L | Kularatna S, Whitty JA, Johnson NW, et al. Valuing EQ-5D health states for Sri Lanka. Qual Life Res. 2015 Jul;24(7):1785-93. | pre-EQ-VT TTO | Sri Lanka 3L (Kularatna TTO 2015).txt | Sri Lanka 3L (Kularatna TTO 2015) | Sri Lanka 3L (Kularatna TTO 2015) |
| Sweden | EQ-5D-3L | Burstrom K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin L, Zethraeus N.Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431-42. | pre-EQ-VT TTO | Sweden 3L (Burstrom TTO 2014).txt | Sweden 3L (Burstrom TTO 2014) | Sweden 3L (Burstrom TTO 2014) |
| Sweden | EQ-5D-5L | Burström K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, Henriksson M. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Pharmacoeconomics. 2020 Aug;38(8):839-856. | Other TTO | Sweden 5L (Bürstrom TTO 2020).txt | Sweden 5L (Bürstrom TTO 2020) | Sweden 5L (Bürstrom TTO 2020) |
| Sweden | EQ-5D-5L | Burström K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, Henriksson M. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Pharmacoeconomics. 2020 Aug;38(8):839-856. | Other VAS | Sweden 5L (Bürstrom VAS 2020).txt | Sweden 5L (Bürstrom VAS 2020) | Sweden 5L (Bürstrom VAS 2020) |
| Sweden | EQ-5D-5L | Sun S, Chuang LH, Sahlén KG, Lindholm L, Norström F. Estimating a social value set for EQ-5D-5L in Sweden. Health Qual Life Outcomes. 2022 Dec 23;20(1):167. | EQ-VT v2.1 | Sweden 5L (Sun TTO 2022).txt | Sweden 5L (Sun TTO 2022) | Sweden 5L (Sun TTO 2022) |
| Sweden | EQ-5D-Y-3L | Åström M, Rolfson O, Burström K. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents. Appl Health Econ Health Policy. 2022;20(3):383-393. | Other | Sweden Y-3L (Aström VAS 2022).txt | Sweden Y-3L (Aström VAS 2022) | Sweden Y-3L (Aström VAS 2022) |
| Taiwan | EQ-5D-3L | Lee HY, Hung MC, Hu FC, Chang YY, Hsieh CL, Wang JD. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan. J Formos Med Assoc. 2013;112(11):699-706. | pre-EQ-VT TTO | Taiwan 3L (Lee TTO 2013).txt | Taiwan 3L (Lee TTO 2013) | Taiwan 3L (Lee TTO 2013) |
| Taiwan | EQ-5D-5L | Lin HW, Li CI, Lin FJ, Chang JY, Gau CS, Luo N, Pickard AS, Ramos Goñi JM, Tang CH, Hsu CN. Valuation of the EQ-5D-5L in Taiwan. PLoS One. 2018 Dec 26;13(12):e0209344. | EQ-VT v2.0 | Taiwan 5L (Lin Hybrid 2018).txt | Taiwan 5L (Lin Hybrid 2018) | Taiwan 5L (Lin Hybrid 2018) |
| Thailand | EQ-5D-3L | Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14(8):1142-5. | pre-EQ-VT TTO | Thailand 3L (Tongsiri TTO 2011).txt | Thailand 3L (Tongsiri TTO 2011) | Thailand 3L (Tongsiri TTO 2011) |
| Thailand | EQ-5D-5L | Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L Valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):551-558. | EQ-VT v1.1 | Thailand 5L (Pattanaphesaj Hybrid 2018).txt | Thailand 5L (Pattanaphesaj Hybrid 2018) | Thailand 5L (Pattanaphesaj Hybrid 2018) |
| Trinidad and Tobago | EQ-5D-3L | Bailey H, Stolk E, Kind P Toward Explicit Prioritization for the Caribbean: An EQ-5D Value Set for Trinidad and Tobago Value in Health Regional Issues; Volume 11; December 2016: 60-67 | pre-EQ-VT TTO | Trinidad and Tobago 3L (Bailey TTO 2016).txt | Trinidad and Tobago 3L (Bailey TTO 2016) | Trinidad and Tobago 3L (Bailey TTO 2016) |
| Trinidad and Tobago | EQ-5D-5L | Bailey H, Jonker MF, Pullenayegum E, Rencz F, Roudijk B. The EQ-5D-5L valuation study for Trinidad and Tobago. Health Qual Life Outcomes. 2024 Jul 2;22(1):51. | EQ-VT v2.1 | Trinidad and Tobago 5L (Bailey Hybrid 2024).txt | Trinidad and Tobago 5L (Bailey Hybrid 2024) | Trinidad and Tobago 5L (Bailey Hybrid 2024) |
| Tunisia | EQ-5D-3L | Chemli J, Drira C, Felfel H, Roudijk B, Al Sayah F, Kouki M, Kooli A, Razgallah Khrouf M. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L. Qual Life Res. 2021 May;30(5):1445-1455 | EQ-VT v2.1 | Tunisia 3L (Chemli Hybrid 2021).txt | Tunisia 3L (Chemli Hybrid 2021) | Tunisia 3L (Chemli Hybrid 2021) |
| Uganda | EQ-5D-5L | Yang F, Katumba KR, Roudijk B, Yang Z, Revill P, Griffin S, Ochanda PN, Lamorde M, Greco G, Seeley J, Sculpher M. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol. Pharmacoeconomics. 2022 Mar;40(3):309-321. | EQ-VT Lite | Uganda 5L (Yang TTO 2022).txt | Uganda 5L (Yang TTO 2022) | Uganda 5L (Yang TTO 2022) |
| United Arab Emirates | EQ-5D-5L | Al Sayah F, Roudijk B, El Sadig M, Al Mannaei A, Farghaly MN, Dallal S, Kaddoura R, Metni M, Elbarazi I, Kharroubi SA. A Value Set for EQ-5D-5L in the United Arab Emirates. Value Health. 2025 Apr;28(4):611-621. | EQ-VT v2.1 | United Arab Emirates 5L (Al Sayah Hybrid 2025).txt | United Arab Emirates 5L (Al Sayah Hybrid 2025) | United Arab Emirates 5L (Al Sayah Hybrid 2025) |
| United Kingdom | EQ-5D-3L | Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-108. | pre-EQ-VT TTO | United Kingdom 3L (Dolan TTO 1997).txt | United Kingdom 3L (Dolan TTO 1997) | United Kingdom 3L (Dolan TTO 1997) |
| United Kingdom | EQ-5D-5L | Rowen D, Mukuria C, Bray N, Carlton J, Longworth L, Meads D, Oluboyede Y, O’Neill C, Yang Y, A UK value set for the EQ-5D-5L, Value in Health (2026), doi: https://doi.org/10.1016/j.jval.2026.03.008 | EQ-VT v2.1 (TTO only) | UK Value Set for the EQ-5D-5L | ||
| England | EQ-5D-5L | Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018 Jan;27(1):7-22. Note: NICE does not recommend using the EQ-5D-5L value set for England by Devlin et al. (2018). For more information, see Section 4.3.16 of the NICE technology appraisal guidance manual. | EQ-VT v1.0 | England 5L (Devlin Hybrid 2018).txt | England 5L (Devlin Hybrid 2018) | England 5L (Devlin Hybrid 2018) |
| United States | EQ-5D-3L | Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3): 203-220. | pre-EQ-VT TTO | United States 3L (Shaw TTO 2005).txt | United States 3L (Shaw TTO 2005) | United States 3L (Shaw TTO 2005) |
| United States | EQ-5D-5L | Craig BM, Rand K. Choice Defines QALYs: A US Valuation of the EQ-5D-5L. Med Care. 2018 Jun;56(6):529-536. | Other | United States 5L (Craig DCE 2018).txt | United States 5L (Craig DCE 2018) | United States 5L (Craig DCE 2018) |
| United States | EQ-5D-5L | Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV. United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value Health. 2019 Aug;22(8):931-941. | EQ-VT v2.0 | United States 5L (Pickard TTO 2019).txt | United States 5L (Pickard TTO 2019) | United States 5L (Pickard TTO 2019) |
| United States | EQ-5D-Y-3L | Pickard AS, Nazari JL, Ramos-Goñi JM, Gu NY. Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States. Value Health. 2025 Nov 26:S1098-3015(25)05689-X. doi: 10.1016/j.jval.2025.11.003. Epub ahead of print. PMID: 41314415. | ||||
| Uruguay | EQ-5D-5L | Augustovski F, Rey-Ares L, Irazola V, Garay OU, Gianneo O, Fernández G, Morales M, Gibbons L, Ramos-Goñi JM. An EQ-5D-5L value set based on Uruguayan population preferences. Qual Life Res. 2016 Feb;25(2):323-333. | EQ-VT v1.1 | Uruguay 5L (Augustovski TTO 2016).txt | Uruguay 5L (Augustovski TTO 2016) | Uruguay 5L (Augustovski TTO 2016) |
| Vietnam | EQ-5D-5L | Mai VQ, Sun S, Minh HV, Luo N, Giang KB, Lindholm L, Sahlen KG. An EQ-5D-5L Value Set for Vietnam. Qual Life Res. 2020 Jul;29(7):1923-1933. | EQ-VT v2.0 | Vietnam 5L (Mai Hybrid 2020).txt | Vietnam 5L (Mai Hybrid 2020) | Vietnam 5L (Mai Hybrid 2020) |
| Zimbabwe | EQ-5D-3L | Jelsma J, Hansen K, De Weerdt W, De Cock P, Kind P How do Zimbabweans value health states? Popul Health Metr 2003; 1(1):11. | pre-EQ-VT TTO | Zimbabwe 3L (Jelsma TTO 2003).txt | Zimbabwe 3L (Jelsma TTO 2003) | Zimbabwe 3L (Jelsma TTO 2003) |
Last update: April 2nd, 2026